BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 5.7% – Here’s What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares were down 5.7% during trading on Thursday . The stock traded as low as $9.96 and last traded at $9.9850. 1,501,871 shares were traded during mid-day trading, a decline of 70% from the average session volume of 4,961,299 shares. The stock had previously closed at $10.59.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BCRX shares. Wedbush decreased their price target on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC cut their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Royal Bank Of Canada lowered their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

The company has a market cap of $2.51 billion, a P/E ratio of -6.53 and a beta of 0.55. The stock has a 50-day simple moving average of $9.44 and a 200 day simple moving average of $8.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals’s quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.15 earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Larson Financial Group LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% during the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the period. Allworth Financial LP acquired a new position in BioCryst Pharmaceuticals in the second quarter worth about $52,000. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals in the third quarter worth about $77,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Finally, Envestnet Portfolio Solutions Inc. acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $81,000. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.